Ask Finn← Discover
YOUR MONEY

Medicare Advantage Insurers Win Major Payment Boost for 2027

By Devin Marsh · Wednesday, April 8, 2026
Finn's Take· TL;DR
  • Medicare Advantage insurers secured 2.48% payment increase for 2027, reversing Trump's January proposal of 0.09% hike and adding ~$13 billion revenue.
  • Major health insurers' stocks surged immediately, with UnitedHealth up 10%, Humana 11%, and CVS 6.9%, reflecting industry relief after months of uncertainty.
  • Higher insurer payments could stabilize benefits and keep premiums modest for 27+ million Medicare Advantage enrollees, but signals administration prioritizes industry profits over cost containment.
See this from any side — with sources:
Left takeNeutralRight take

Trump Administration Reverses Course on Medicare Payments

Health insurance giants scored a massive victory Monday when the Trump administration announced Medicare Advantage payments will increase by 2.48% in 2027, significantly higher than the proposed payment rate hike of 0.09% that the government floated in January . The decision represents a dramatic reversal that will pump an estimated $13 billion in additional revenue to insurers next year .

The Trump administration also scrapped a proposal that would have used more updated data in the payment process, ensuring that Medicare Advantage insurers retain billions of dollars . This policy change alone provides substantial relief to an industry that has faced mounting regulatory pressure and rising medical costs in recent years.

The announcement triggered an immediate surge in health insurance stocks. UnitedHealth's stock jumped as much as 10%, the most intraday since August, while Humana advanced as much as 11% and CVS Health gained as much as 6.9% . These three companies together cover almost 60% of all people enrolled in the Medicare Advantage program .

Industry Relief After Months of Uncertainty

The generous payment increase comes as welcome news for insurers who had braced for much tighter margins. When the Trump administration proposed in January holding payment rates essentially flat for 2027, the selloff in health insurers that provide Medicare Advantage plans wiped out nearly $100 billion in stock market value.

While one analyst noted the rate increase isn't "so awesome in a vacuum," it's "certainly better" than the initial proposal and may help companies expand margins in 2027 if they keep reducing benefits and managing expenses . The decision signals that the new administration is willing to work with industry concerns rather than pursue aggressive cost-cutting measures.

Analysts viewed this as a positive sign that CMS and the administration were willing to listen to industry participants, with the changes improving plan revenue visibility and easing concerns tied to earlier policy proposals .

What This Means for Medicare Beneficiaries

The payment boost could have mixed implications for the millions of Americans enrolled in Medicare Advantage plans. More than half of Medicare beneficiaries are enrolled in Advantage plans, enticed by lower monthly premiums and extra benefits not covered by traditional Medicare . Higher payments to insurers could help stabilize these benefits and potentially keep premium increases modest.

However, the decision also highlights ongoing tensions around Medicare Advantage costs. In recent years, concerns about costs and how insurers maximized their payments under obscure policies brought more scrutiny to the program, with the Biden administration trimming rates and beginning to change the payment system, causing several insurers to struggle to profit on Medicare .

Looking Ahead to 2027 and Beyond

The payment increase provides insurers with crucial breathing room as they navigate an increasingly complex healthcare landscape. UnitedHealth's annual sales are expected to rebound and rise 4% in 2027 to $457.29 billion, while annual earnings are projected to spike 13% to $19.95 per share .

The decision also sets the stage for how the Trump administration will approach healthcare policy more broadly. By choosing to support industry profitability over aggressive cost containment, the administration signals a markedly different approach from its predecessor. This shift could influence everything from drug pricing policies to hospital reimbursement rates as the healthcare sector watches for additional regulatory changes.

Have a question about this story?
Ask Finn — answers grounded in this article, from any viewpoint.